Key Drivers
- Cash Conversion
- Margin Compression
- Liquidity Erosion
AIAI Summary
BDX has shifted from a low-growth defensive medtech name to a self-help story with real per-share upside from strong cash generation and buybacks, but the investment case still hinges on management clearing the FDA ship-hold and proving it can protect margins from tariffs and commercial spending.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Conversion
- •Margin Compression
- •Liquidity Erosion
BDX delivered solid full-year cash generation, but the latest quarter showed sharply weaker profitability, liquidity, and interest coverage, making the investment case dependent on sustained cash flow at a relatively rich valuation.
Price Behavior
Key Price Behavior Insights:
- •Rebound breakout
- •Higher closes
- •Hold support
BDX has turned constructively higher over the last month after rebounding from its June low and breaking to a new high, but it needs to hold the $151.33–$152.90 area to avoid a pullback into the prior range.
Sharp drawdown from
Sentiment & News
Key News Insights:
- •Undervalued Valuation
- •Dividend Support
- •Reimbursement Risk
BDX is being viewed as an undervalued, defensive MedTech name with steady dividend/buyback support and incremental innovation wins, though reimbursement uncertainty remains a key overhang.
The news flow is mildly positive for BDX, reinforcing its income appeal while innovation progress helps offset ongoing sector-level reimbursement concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings